Cancer
- Latest Posts
News and Trends 6 Jun 2023
Shasqi using click chemistry to target cancer
Shasqi, Inc., whose mission is to revolutionize cancer treatment with click chemistry, has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc. Through the collaboration, Shasqi will apply its tumor-targeted Click Activated Protodrugs Against Cancer (CAPAC) platform to the development of new cancer therapies. Shasqi’s CAPAC platform relies on chemistry, not biology, […]
Podcast 2 Jun 2023
Beyond Biotech podcast 48
BioInvent International AB, a Swedish biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, recently announced positive phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. BioInvent currently has four […]
News and Trends 2 Jun 2023
New approach improves cancer treatment and minimizes side effects
Scientists at Tohoku University in Japan have discovered a new approach to improve the efficacy of immune checkpoint blockade (ICB) – a novel form of cancer treatment utilizing immune checkpoint inhibitors (ICIs) – while minimizing the associated side effects. They demonstrated that using ICIs to target tumor-positive lymph nodes generates a robust anti-tumor response against […]
News and Trends 2 Jun 2023
Anocca raises $36.6M for large-scale development of cancer cell therapies
Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […]
News and Trends 30 May 2023
Pancreatic cancer microbiome discovery holds treatment hope
iNtRON Biotechnology has announced the identification of prophage and (non-) ORF-jamphage from the microbiome frequently observed in long-term pancreatic cancer survivors. The company said the ‘significant identification’ was achieved as part of its ongoing PHAGERIARUS development project conducted by the new drug part of the company. The PHAGERIARUS development project is focused on acquiring bacteriophage-derived […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 30 May 2023
Potential targets against natural killer/T-cell lymphoma found
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has discovered that a transcription factor, TOX2, was aberrantly increased in patients with natural killer/T-cell lymphoma (NKTL). The increased TOX2 level leads to the growth and spread of NKTL, as well as the overproduction of […]
News and Trends 30 May 2023
Molecular Partners presenting positive solid tumor data
Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to 6 in Chicago, U.S. The […]
Podcast 26 May 2023
Beyond Biotech podcast 47
The companies Daiichi Sankyo and AstraZeneca have worked together for several years. This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca. On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining […]
News and Trends 26 May 2023
Transgene and BioInvent report positive solid tumor results
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, have announced positive phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent […]
News and Trends 25 May 2023
PharmEnable raises $7.5M to develop small molecule drugs to treat cancer and neurological diseases
PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi […]
News and Trends 24 May 2023
Major progress as Swedish scientists get brain tumors to self destruct
Researchers at the University of Gothenburg in Sweden, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma. By blocking certain functions in the cell with a docked molecule, the researchers cause the cancer to die of stress.Cancer cells, especially those that form aggressive tumors, are in one […]
ADVERTISEMENT
